SMARCA4 and non-small cell lung carcinoma: We also found that of the prevalent genomic aberrations reported to modify responses to targeted RAS pathway inhibition with approved KRASG12C inhibitors (32, 33), mutations in SMARCA4 were not associated with impaired RMC-6236 effects on durability of response in KRASG12X NSCLC xenograft models, while KEAP1 mutation or loss of CDKN2A expression were associated with a less durable response, opening the door for rational combinations to enhance durability.